N@N

Market Maker Surveillance Report. BPAX, FFHL, DARA, ACAD, AHPI, XOMA, Losing Stocks With Lowest Price Friction For Tuesday, De

^{Published on 2010-12-28 17:51:04 - WOPRAI}
 

December 28, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 2573 companies with "abnormal" market making, 2381 companies with positive Friction Factors and 3104 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX), Fuwei Films (Holdings) Co. Ltd. - ORDINARY SHARES (NASDAQ:FFHL), DARA BIOSCIENCES INC (NASDAQ:DARA), ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD), ALLIED HEALTHCARE PRODUCTS (NASDAQ:AHPI), XOMA LTD (NASDAQ:XOMA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     BPAX       $-0.380      -19.00%      3,813,068       45.27%       4,609,397       54.73%       -796,329        -20,956 
     FFHL       $-0.500      -12.59%      106,061         40.41%       151,969         57.91%       -45,908         -918    
     DARA       $-0.770      -19.74%      480,968         44.63%       569,145         52.81%       -88,177         -1,145  
     ACAD       $-0.150      -11.54%      833,602         32.81%       1,707,379       67.19%       -873,777        -58,252 
     AHPI       $-0.890      -19.39%      32,985          30.46%       75,095          69.35%       -42,110         -473    
     XOMA       $-1.370      -22.31%      10,820,388      47.77%       11,811,904      52.14%       -991,516        -7,237  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows XOMA with a dollar loss Tuesday of $-1.37000 and a Friction Factor of -7,237 shares. That means that it only took 7,237 more shares of selling than buying to move XOMA lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

BIOSANTE PHARMACEUTICALS INC (NASDAQ:BPAX) - BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. The company offers Elestrin, a transdermal estradiol (estrogen) gel, which is marketed in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. It also develops LibiGel, a transdermal testosterone gel that is in Phase III development for the treatment of female sexual dysfunction; Pill-Plus, which is a combination of estrogens, progestogens, and androgens for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives; and Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men. In addition, the company develops calcium phosphate technology (CaP) for aesthetic medicine, as a vaccine adjuvant, and for drug delivery. Its CaP products in development comprise BioLook, which is a facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant, a CaP adjuvant and delivery technology for vaccines against viral and bacterial infections and autoimmune diseases; BioOral, a delivery system for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system for inhalable versions of proteins and other therapies. The company was founded in 1996 and is based in Lincolnshire, Illinois.

Fuwei Films (Holdings) Co. Ltd. - ORDINARY SHARES (NASDAQ:FFHL) - Fuwei Films (Holdings) Co. Ltd. - ORDINARY SHARES

DARA BIOSCIENCES INC (NASDAQ:DARA) - DARA BioSciences, Inc., a development-stage pharmaceutical company, acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. The company has two drug candidates in development with cleared investigational new drug applications from the U.S. Food and Drug Administration. Its drug development programs include KRN5500, which completed a Phase IIa clinical trial for the treatment of neuropathic pain in cancer patients; and DB959 for the treatment of metabolic diseases, including type 2 diabetes. The company is headquartered in Raleigh, North Carolina.

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company is developing a portfolio of four product candidates, including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail. These indications include Parkinsons disease psychosis that is in Phase III development; adjunctive therapy for schizophrenia, which is in Phase III planning; and Alzheimers disease psychosis, for which ACADIA is planning to initiate a Phase II feasibility study. The company also has other products under development, including a product candidate in Phase II development for chronic pain; and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a program in IND-track development in collaboration with Meiji Seika Kaisha. The products in ACADIAs pipeline emanate from discoveries made using its proprietary drug discovery platform. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.

ALLIED HEALTHCARE PRODUCTS (NASDAQ:AHPI) - Allied Healthcare Products, Inc. engages in the manufacture, marketing, and distribution of respiratory products. The company provides respiratory care products, medical gas equipment, and emergency medical products. Its respiratory care product line comprises respiratory care/anesthesia products, such as air compressors, calibration equipment, humidifiers, croup tents, equipment dryers, and respiratory disposable products; and home respiratory care products, including aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, and portable suction equipment. The companys medical gas equipment product portfolio includes construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment, such as flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure and regulate transfer of medical gases to patients in hospital rooms, operating theaters, or intensive care areas; and disposable cylinders that offer oxygen for short periods of time in emergency situations. Its emergency medical product line comprises respiratory/resuscitator products, including demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products, such as spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. The company offers its products to hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, and emergency medical product dealers through a network of dealers, agents, and exporters. It operates in the United States, Canada, Mexico, Central and South America, Europe, the Middle East, and the Far East. The company was founded in 1979 and is headquartered in St. Louis, Missouri.

XOMA LTD (NASDAQ:XOMA) - XOMA Ltd., incorporated in 1981, is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company has a royalty interest in one approved therapeutic antibody, RAPTIVA, which is marketed in the United States, Europe and elsewhere, for the treatment of moderate-to-severe plaque psoriasis. XOMA also has a future royalty interest in additional therapeutic antibody product candidates being developed by others as a result of licensing its technologies. XOMA's pipeline includes both products and collaborative programs at various stages of preclinical and clinical development primarily directed toward treatments for cancer and immune disorders. In addition to supporting its product pipeline, the Company uses its infrastructure to provide process development and manufacturing services on a fee-for-service basis.

RAPTIVA (Efalizumab)

The Company markets RAPTIVA under an agreement with Genentech, Inc. as a result of a prior collaborative product development program. RAPTIVA is a humanized therapeutic monoclonal antibody developed to treat immune system disorders. RAPTIVA can be self-administered by patients as a single, once-weekly subcutaneous injection. In 2005, Serono had launched RAPTIVA in over 40 countries worldwide.

RAPTIVA competes with Enbrel from Amgen Inc. and its partner Wyeth Pharmaceuticals; Amevive from Biogen Idec Inc.; BG-12 from Biogen Idec Inc. and Fumapharm AG; Remicade from Centocor, Inc. Humira from Abbott Laboratories, and ISA247 from Isotechnika, Inc.

CHIR-12.12

CHIR-12.12, which is being developed by the Company in collaboration with Chiron Corporation, is an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies. In April 2005, XOMA announced the initiation of Phase I study for patients with advance chronic lymphocytic leukemia (CLL). Then in October 2005, the Company initiated a second Phase I study for patients with multiple myeloma (MM).

NEUPREX (opebacan/rBPI21)

NEUPREX (opebacan/rBPI21) is an injectable formulation of rBPI21, a modified recombinant fragment of human bactericidal/permeability-increasing protein (BPI). BPI is a human host-defense protein made by a type of white blood cell that is involved in the body's defenses against microbial infection. In October of 2003, in conjunction with Children's Medical Center Dallas, the Company announced the initiation of an open-label, single center, dose escalation, investigator-sponsored, Phase I/II clinical trial of NEUPREX in pediatric patients with congenital heart abnormalities requiring open heart surgery associated with cardiopulmonary bypass.

XMA005.2

XMA005.2 is a Human Engineered monoclonal antibody with a high-affinity and potent inhibitory activity against its inflammatory target. This high potency means that it may be suitable for use as a monthly-dose injectable therapeutic. XOMA is evaluating XMA005.2 in preclinical studies targeting multiple indications, including osteoarthritis and rheumatoid arthritis, where less frequent dosing could be a significant marketing advantage.

Anti-gastrin Mab

In September of 2004, XOMA announced a worldwide collaboration with Aphton Corporation to develop treatments for gastrointestinal (GI) and other gastrin-sensitive cancers using anti-gastrin monoclonal antibodies. Gastrin has been shown to be involved in the progression of colorectal, stomach, liver and pancreatic cancers and inhibiting gastrin may inhibit such growth.

Metabolic Disease Target

The Company is co-developing Metabolic Disease Target with Lexicon Genetics. Metabolic Disease Target is a secreted protein involved in metabolic functions such as insulin sensitivity and weight gain that was identified through Lexicon's Knockout Technology. Antibodies to this target may be developed to treat Type II diabetes, obesity and other metabolic diseases.

MLN2222

MLN2222 (also known as CAB2) is being developed by XOMA in partnership with Millennium Pharmaceuticals, Inc. MLN2222 is a complement inhibitor for coronary artery bypass graft surgery tar

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net